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Abstract (239 words) 
Background: Previous studies on the putative role of allergy in the aetiology of childhood leukaemia 
have reported contradictory results. The present study aimed to analyse the relation between a medical 
history of asthma or eczema and childhood acute lymphoid leukaemia (ALL) in light of potential 
candidate gene-environment interactions. 
Methods: Analyses were based on a subset of 434 cases of ALL and 442 controls successfully 
genotyped and of European ancestry children enrolled in a French population-based case-control study 
conducted in 2003-2004. Information about medical history was obtained during a standardized 
interview with the mothers. Candidate polymorphisms in genes of the Th2 cytokines IL4, IL10, IL13 
and IL4-receptor, were genotyped or imputed. 
Results: None of the variant alleles were directly associated with childhood acute lymphoid 
leukaemia. A medical history of asthma or eczema was reported more often in the control group 
(OR=0.7 [0.5-1.0]). This association was mostly seen in the group of children not carrying the IL13-
rs20541 variant allele (Interaction Odds Ratio IOR 1.9, p-interaction=0.07) and in those carrying the 
IL10 triple variant haplotype (IOR 0.5, p-interaction=0.04). No interaction was observed with the 
candidate polymorphisms in IL4 and IL4R. 
Conclusion: This study provides a new insight into the relationship between allergic symptoms and 
childhood acute lymphoid leukaemia, by suggesting this inverse association could be limited to 
children carrying certain genetic polymorphisms. If confirmed, these results could help better 
understand the biological mechanisms involved in the development of childhood acute lymphoid 
leukaemia. 
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1. Introduction 
Acute lymphoid leukaemia (ALL) accounts for approximately 80% of all childhood acute leukaemias 
and a quarter of all childhood neoplasms in developed countries. Little risk factors have been 
identified to date, i.e. high-level ionizing radiation, certain chemotherapeutic agents, Down's syndrome 
and a few rare genetic disorders. It has long been hypothesized that a lack of immune stimulation 
through exposure to infectious agents in infancy and early childhood could be related to the 
development of ALL1, although the epidemiological evidence is still contradictory2. To some extent, 
this parallels the hygiene hypothesis, which postulates that a lack of early immune stimulation could 
be associated with the rising incidence of allergies in developed countries. From these, one could 
expect atopy and allergy to be positively associated with childhood leukaemia. However, most 
questionnaire-based epidemiological studies reported an inverse association between atopy or allergy 
and childhood leukaemia, as reviewed by Linabery3 , 4.  
In the last few years, in an attempt to rely on unbiased sources of information, several publications 
have studied the association between atopy or allergy and childhood leukemia relying on objective 
sources of information, such as medical records5, 6, health claim data7, and IgE levels at recruitment8. 
Some of those studies5, 8 corroborated the inverse association between allergy and childhood 
leukaemia found in the interview-based studies, whereas two other studies did not find this 
association6, 7. Recently, a Mexican study reported a positive association borderline of significance 
between bronchial asthma and ALL in children with Down syndrome9. 
Despite the increasing biological knowledge, the mechanisms leading to allergy still need to be 
unraveled. A role of Th2 cytokines has long been suspected in the etiology of allergy, supported by the 
key regulatory effects of the interleukins produced by T-lymphocytes undergoing a Th2 
differentiation, such as interleukins (IL) IL4, IL10 and IL13. Additionally, some studies have reported 
associations between asthma and polymorphisms in the genes coding for IL13, IL4, IL10 and IL4R10-
13. Polymorphisms in IL13 and IL4R were also associated with allergic rhinitis, wheeze atopic 
dermatitis in an international study14.  
The role of interleukins in childhood leukaemia has been little investigated. In a Californian study, the 
levels of IL10 at birth were significantly lower in ALL cases than in controls15. In the same study, a 
genomic analysis showed a slight association between ALL and IL10 tag-SNPs (Single Nucleotide 
Polymorphisms)16. Recently, two polymorphisms in IL10 were reported to be associated with 
childhood leukaemia in Taiwan17. 
The aim of the present study was to provide a new insight in the relationship between allergic 
disorders and childhood ALL by taking into account genetic polymorphisms of several Th2 cytokines, 
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namely interleukins IL4, IL10, IL13 and IL4-receptor, suspected to be involved in the development of 
allergy. 
 
2. Material and methods 
2.1. Study 
Study design and sampling have been extensively described elsewhere18, 19. Briefly, the ESCALE 
study is a population-based case-control study conducted in France in 2003-2004. Eligible children 
were residing in mainland France, had not been adopted, and had a living French-speaker biological 
mother without a serious psychiatric disorder. 
Children diagnosed with leukaemia before the age of 15, between 01/01/2003 and 31/12/2004, were 
detected and recruited using the detection system of the French national childhood haematological 
malignancies registry. Children who were deceased or under palliative care were ineligible. Out of the 
714 eligible children diagnosed with acute lymphoid leukaemia, 648 were enrolled in the study 
(participation rate 91%).  
Controls were randomly selected from the general population using random digit dialing 
contemporaneously with the recruitment of the cases. Quotas were applied to obtain a control group 
comparable to the whole case group (leukaemias, lymphomas, CNS tumours and neuroblastomas) in 
terms of gender and age (0-1, 2, 3, 4, 5-6, 7-8, 9-11, 12-14 years) and to the general population 
regarding the number of children living in the household. The participation rate of the controls was 
71%, so that 1,681 controls were enrolled out of the 2,361 eligible children.  
2.2. Information on medical history 
Information about socio-demographic characteristics and suspected risk factors, such as maternal 
exposures during pregnancy, perinatal characteristics, personal and familial medical history was 
obtained over the telephone. The children biological mothers were interviewed using a standardized 
questionnaire identical for cases and controls. Before the interview, mothers were asked to have a copy 
of the child health record on hand, so they could get back to the records if needed.  A large proportion 
of mothers followed this recommendation (97.2%  for ALL cases and 98.2% for controls). Mothers 
were specifically asked whether the participating child had developed asthma or eczema, and, if so, the 
age at onset. Moreover, a specific item regarded regular intakes of bronchodilators, corticoids, or 
antihistamines/anti-allergic drugs. 
Reported medical history of asthma and eczema were analysed as independent variables. More 
specific variables were also analysed, considering a latency period of one year by ignoring the  asthma 
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or eczema diagnoses that occurred in the year prior to the age at diagnosis (for cases) or recruitment 
for controls).For asthma, we also considered the reported treatments with antihistamines, corticoids or 
bronchodilators. 
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2.3. Biological specimens 
Biological specimens were requested from each participant. They consisted in blood samples taken 
from cases during care, prior to initiation of chemotherapy, and saliva taken at home using swab 
brushes for the controls. Biological samples were obtained from 619 ALL cases (96%) and 810 
controls (48%). 
After DNA extraction, a sufficient DNA quantity was available for genotyping of 513 ALL cases and 
570 controls. Cases were genotyped on an Illumina 370k Quad platform (283,027 single nucleotide 
polymorphisms [SNPs]), and a custom iSelect platform (4,868 SNPs) was used for the controls. The 
comparability of the two genotyping methods was assessed and confirmed by re-genotyping 96 
randomly-selected cases on the platform used for the controls (100% agreement). Fulfilled quality 
checks, including a call-rate >97% for the cases and 95% for the controls, and a 46, XX or 46, XY 
formula were considered mandatory criteria for subsequent genetic analyses, leading to the exclusion 
of 42 ALL cases (including 6 children with Down syndrome) and 109 controls. 
A principal component analysis (PCA) using information from 96,609 SNPs was performed in the 
case group in order to determine the Caucasian origin from the CEPH (Human Polymorphism Study 
Center). Because of the platform used for genotyping the controls, such a PCA could not be performed 
for the control group. However, in the case group, having at least two European-born grandparents, a 
proxy variable derived from the questionnaire, showed to be very predictive of the CEPH 
classification (sensitivity 98.2%, specificity 94.3%)20. Assuming that this proxy variable was as good a 
predictor in the control group, it was used to restrict both the case and control samples on European 
ancestry, in order to limit the potential for population stratification bias. 
Finally, 434 cases with ALL and 442 controls, all genotyped children of European ancestry (≥ 2 
grandparents born in Europe), were available for the present analysis. 
2.4. Genotyping of candidates SNPs 
Polymorphisms in Th2 cytokines genes (IL4, IL10, IL13 and IL4R) were identified through a literature 
search and selected a priori as a sample of SNPs having been reported to be associated with allergy, 
asthma10-13, or with IgE level14. Additional selection criteria were the effect of the genotype on the 
protein function or production level, and its availability after genotyping. Those polymorphisms 
selected for analysis were the haplotype rs2070874-rs2243250 in IL4, rs20541 in IL13, rs1801275 in 
IL4R and the haplotype rs1800896-rs1800871-rs1800872 in IL10.  
The polymorphisms that could not be genotyped on the cases’ platform, namely IL4-rs2070874 and 
rs2243250, IL10-rs1800871 and rs1800872, or that showed evidence of genotyping errors in the 
controls (departure from Hardy-Weinberg), e.g. IL10-rs1800896 and IL4R-rs1801275, were imputed 
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using the Impute V2 software21. Information for imputation was obtained from all SNPs genotyped in 
our participants in the 100,000 bp in the vicinity of the gene, and using the CEU samples from the 
HapMap and 1000 Genomes projects (respectively, HapMap 43 release 28 CEU, phases 1, 2 and 3 
[http://hapmap.ncbi.nlm.nih.gov], 1000 Genomes phase pilot 1-low coverage 
[http://www.1000genomes.org]) as reference panels. Inferred genotypes were further considered for 
analyses when the post-imputation probability reached at least 90%. However, sensitivity analyses 
were conducted using a 0.80 cutoff. Additionally, the quality of imputation was assessed for each 
SNP, by the Info and Certainty criteria provided by Impute V2 software. 
The genotypes were analysed separately, and then assuming a dominant model of expression (carrying 
at least one variant allele vs. none). Since some SNPs in IL4 and IL10 (IL4-rs2070874 and rs2243250; 
IL10-rs1800871 and rs1800872) have been shown to be in linkage disequilibrium, the haplotypes were 
deduced from the genotypes. The haplotypes for IL4 rs2070874-rs2243250 were CC (reference 
haplotype) and TT (double variant haplotype), and those for IL10 rs1800896-rs1800871-rs1800872 
were CGG (reference haplotype), TGG and the triple variant TAT haplotype. 
2.5. Statistical analyses 
For each SNP, the Hardy-Weinberg equilibrium test was systematically performed in the group of 442 
controls of European ancestry, and there was no evidence of a departure from the equilibrium. 
Unconditional logistic regression models were used to compare cases and controls with regards to 
their history of asthma or eczema, and genotypes. All analyses presented hereafter were adjusted for a 
gender*age variable, birth order, maternal highest diploma, and professional category of the 
household20. Interactions were assessed using likelihood ratio tests. 
 
3. Results 
3.1. Study sample 
The table 1 shows a brief description of the subsample of genotyped children of European ancestry. 
The distribution of gender was not different in cases and controls, but controls tended to be globally 
older than ALL cases. Cases were more likely than controls to be first-born children, and not to have 
been breastfed. The parental socio-professional characteristics were differently distributed, with higher 
educational levels and higher professional category in the control group. Common precursor-B cell 
leukaemia was the most common subtype (n=355), with the group of genotyped cases also including 
less common subtypes, such as pro-B (n=10), mature B-cell (n=19), T-cell (n=40) and other types of 
lymphoid leukaemia (n=40). 
3.2. Association between asthma or eczema and childhood ALL 
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In this subsample of 434 ALL cases and 442 controls genotyped and of European origin, asthma and 
eczema were both inversely associated with the occurrence of childhood ALL (respective OR=0.6 
[0.4-1.1] and 0.8 [0.5-1.1]) (table 2), as observed in the whole ESCALE study18. These associations 
were also observed when considering a latency of 1 year, and when changing the definition of 
asthmatic children to those treated with anti-allergic, bronchodilators or corticoid drugs. Having a 
history of either asthma or eczema was significantly associated with childhood ALL with the same 
order of magnitude (OR=0.7 [0.5-1.0]). Associations were unchanged when histories of asthma and 
eczema were mutually adjusted for.  
3.3. Association between candidate polymorphisms and childhood ALL 
Table 3 shows the associations between the candidate polymorphisms in IL13, IL10, IL4 and IL4R 
genes and childhood ALL. None of the genotypes of the candidate SNPs analysed separately were 
associated with childhood ALL. The IL4 double variant haplotype (TT haplotype) was little associated 
with childhood ALL (OR=1.3 [0.9-1.8], p=0.14), but the IL10 TAT triple variant haplotype was not 
associated with ALL. 
3.4. Gene-gene  and gene-environment interactions 
The analyses suggested a gene-gene interaction between IL4 TT haplotype and IL13-rs20541 (IOR 
1.8, p=0.10), between IL13-rs20541 and IL10 TAT haplotype (IOR 0.6, p=0.10), and between IL4 TT 
haplotype and IL4R-rs1801275 (IOR 1.8, p=0.07), , despite lack of statistical significance (table 4).  
The analyses of interaction between a reported medical history and the candidate polymorphisms are 
shown in table 5. The results suggested there might be an interaction between IL13-rs20541 and a 
medical history of asthma or eczema. Indeed, the inverse association between childhood ALL and 
asthma/eczema was only seen in the group of children carrying no variant allele (OR=0.5 [0.4-0.8] vs. 
OR=1.1 [0.6-1.9] in the carrier group [not shown], interaction test p=0.07). There was also some 
evidence of an interaction with the IL10-TAT haplotype, with the association between a history of 
asthma or eczema and childhood ALL observed in those carrying the triple variant haplotype 
(IOR=0.5 [0.2-1.0], p interaction 0.04). There was no evidence of an interaction between 
asthma/eczema and IL4 or IL4R polymorphisms. 
3.5. Sensitivity analyses 
Similar patterns of interaction were observed after taking into account a one-year latency, and 
lowering the imputation probability cutoff to 0.80.  
All analyses repeated with a further adjustment for repeated infections in infancy, maternal pesticides 
use during pregnancy, paternal smoking before conception, familial history of cancer, and road traffic 
showed compatible estimates, although the association between a history of asthma or eczema and 
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childhood ALL was weaker (OR=0.8 [0.6-1.1]). Adjusting all models for attendance to full-time day 
care before the age of 1 year did not change the results. We also repeated the analyses adjusting for the 
number of grandparents born in Europe (2, 3 or 4) and the results did not change. 
The associations between the various SNPs in IL4 and IL10 and asthma or eczema in the control group 
were compatible with the positive associations reported in previous literature, with OR estimates 
ranging between 1.2 and 1.4, although not reaching statistical significance (dominant model, data not 
shown). However, the association with IL13-rs20541 and IL4R-rs1801275 (OR=0.8 [0.5-1.2] and 
OR=0.9 [0.6-1.4]) did not replicate the associations found in previous studies.  
All analyses were repeated in the 422 cases and 434 controls whose mother had a copy of the medical 
record at the interview, and showed similar results. 
 
4. Discussion 
4.1. Main results 
Not only do our results support an inverse association between childhood ALL and a reported history 
of asthma or eczema, but they suggest that this association could depend on the children’s genotypes 
for Th2 cytokine genes. Indeed, in this study, the inverse association was essentially observed in 
individuals not carrying the variant IL13-rs20541 allele, and in those carrying the IL10 TAT 
haplotype.  
4.2. Strength and limits 
The registry-based methods used for the identification of the eligible cases and the high participation 
rate ensured that the recruitment of cases was nearly exhaustive. Only 41 leukaemia cases were not 
eligible for medical reasons, being dead or under palliative care, which is unlikely to have biased our 
results. Biological sampling was generally well accepted in this population-based study, and later 
decreases in numbers were mainly due to unsuccessful genotyping. 
The controls were randomly selected from the general population with quotas on the sex and age 
distributions ensuring comparability with the cases. Moreover, the selection process made the control 
group representative of the general population in terms of region and number of children living in the 
household. In the control group, the age at recruitment, parental education level and professional 
category were related to the acceptance and success of the genotyping, the latter being probably due to 
the sampling method (saliva). These variables were considered potential confounders and all analyses 
were systematically adjusted for them. 
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It was not possible to run a PCA to determine whether controls were of Caucasian origin because the 
genotyping platform used for the controls had much fewer SNPs than the one used for the cases. In 
order to limit the possibility of a population stratification bias, we however restricted our study to 
children with a European ancestry as derived from the country of birth of their grandparents. In the 
ESCALE study, this variable  was found to be a good proxy for the Caucasian origin in the case 
group20. The comparability of the different genotyping platforms used for cases and controls was 
assessed by re-genotyping 96 cases on the controls platform. 
Because of the apparent discrepancy in published results between interview-based studies and two of 
the studies relying on medical and administrative data, misclassification bias is a particular concern 
when studying the relationship between a reported history of allergy and childhood ALL. In the 
ESCALE study, mothers were asked about the index child’s medical history, and they were 
encouraged to use the child health record as a support for answering. Additional analyses showed 
robust results when restricted to children whose mother had the health record on hand during the 
interview. The questions about the age at onset and related treatments gave additional information to 
classify children on their medical history. The frequency of asthma in the ESCALE control group was 
very close to that observed in another French study22 (respectively 11.1% and 12.7% of the 11-14 
year-old children). Applying a one-year latency and restricting the definition of asthma to those under 
treatment did not change the magnitude of the association with childhood ALL, although leading to 
higher p-values. Because asthma and eczema can occur without a proper allergy and, conversely, 
allergy can manifest itself with other symptoms, the present results have a limited generalizability 
regarding allergy in childhood.  
Candidate SNPs were selected for their potential association with allergy or symptoms, and their 
functional consequences. We used imputation to infer the genotypes for 4 SNPs in IL4 and IL10 that 
were not available in the case sample after genotyping, under strict quality criteria (Info and Certainty, 
post-imputation probability). To be considered for analysis, an individual genotype had to be imputed 
with a very high probability. Still, the sensitivity analyses showed that the results were robust to a 
lower imputation probability cutoff.  
The power conditions to detect an interaction with IOR=2 between a reported history of asthma or 
eczema (frequency≈20%) and the various candidate polymorphisms (frequency ranging from 25% to 
40%) in the subsample of 434 ALL cases and 442 controls were moderate, between 47% and 53%. 
Our study might have suffered from under-power to detect interactions with small effect. However,  
our analyses highlighted two interactions between a reported history of asthma or eczema and both 
IL10 TAT haplotype and IL13-rs20541 alleles. Due to the number of tests performed, caution is 
required with regards to the interpretation of the p-values and these findings need replication. 
4.3. Comparison with previous literature 
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Showing a negative association between ALL and history of asthma or eczema in the ESCALE study 
is in line with the results of most of the interview-based studies reporting on the association between 
allergy and childhood leukaemia23-26. A concern has been raised about the consistency of this inverse 
association, since two studies relying on objective data did not replicate this finding6, 7. On the other 
hand, in a study using medical diagnoses from the children’s medical record5, an inverse association 
was also found between childhood ALL and the definite diagnoses of allergy, eczema and hay fever. A 
meta-analysis by Linabery et al3 replicated the overall inverse association between atopy/allergy and 
childhood ALL, and underlined the lack of robustness of this association when taking into account a 
latency period. In the ESCALE study, the available data allowed taking into account a one-year 
latency and, although limited by numbers, those analyses showed an inverse association of the same 
order of magnitude.  
The genotypic analyses showed a non-significantly raised OR related to the IL4 haplotype, but not 
with IL10 promoter haplotype that is related to a decrease in IL10 synthesis. In the NCCLS, Chang et 
al16 had found a slight association between three tag-SNPs in IL10 gene and childhood ALL that was 
not robust when taking into account multiple testing. In the same Californian study15, the analysis of 
blood samples taken at birth showed that cases featured lower IL10 levels than controls, whereas the 
levels of other Th1 and Th2 cytokines, including IL4 and IL13, were not different. Our results further 
suggest that the suspected negative association between childhood ALL and a medical history of 
asthma or eczema could be limited to children carrying certain genetic polymorphisms, such as the 
IL10 promoter TAT haplotype or the IL13-rs20541 GG genotype. Unlike with IL10, the interaction 
with IL13 could partly explain the discrepancies observed with the US6 and Taiwanese7 studies. 
Indeed, genotyping from the 1000 Genomes project (phase 1) showed a lower proportion of IL13-
rs20541 GG genotype in people with Asian (42.7%, ASN sample) or Mexican ancestry (19.7%, MXL 
sample) than in those with European ancestry (60.0%, CEU sample).  
The inverse occurrence of allergy and childhood ALL suggested by epidemiological studies remains 
largely unclear. There is a growing body of evidence for a protective effect of a highly-active immune 
system against leukaemia, with studies having found an inverse association between childhood acute 
lymphoblastic leukaemia and allergy and early immune stimulations indicators such as daycare in 
infancy2, 27 and breastfeeding2, 28. Immune responses are normally inhibited by the regulatory T cells 
(Treg), thus avoiding allergy and autoimmune diseases. As explained by the “reduced immune 
suppression” hypothesis, a lack of Treg stimulation could lead to inappropriately overactive Th1 and 
Th2 responses29, which, one could hypothesize, could promote both allergy and the expansion of 
preleukaemic cells. Interestingly, this hypothesis aligns with the deficit in IL10, regulatory cytokine 
also produced by Treg cells, reported at birth in ALL cases by Chang and colleagues15. 
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In conclusion, this study suggests that the association between allergic phenotypes and childhood ALL 
could be modified by genetic polymorphisms of Th2 cytokines such as IL13 and IL10. While these 
results warrant further replication, they provide further evidence for a reduced risk of ALL among 
children developing allergic symptoms, and suggest that this association could be related to immune 
suppression mechanisms involving IL10.   
Acknowledgements 
The authors are grateful to Claire Mulot, who was in charge of the biological collection at the 
Biological Resource Center of Saints-Pères, INSERM U775; the CEPH and the Centre National de 
Génotypage, who genotyped the cases; and IntegraGen, who genotyped the controls. We also thank 
Florence Demenais and the UMR-946 unit (Inserm-Université Paris Diderot) and Fondation Jean 
Dausset-CEPH for their support. The authors would also like to express their gratitude to: Marie-
Hélène Da Silva, Christophe Steffen and Florence Menegaux (INSERM U1018, Environmental 
Epidemiology of Cancer), who contributed to the recruitment of the cases; Aurélie Guyot-Goubin and 
the staff of the French National Registry of Childhood Hematopoietic Malignancies, who contributed 
to case detection and verification; and Sabine Mélèze and Marie-Anne Noel (Institut CSA), who 
coordinated the selection of the controls. 
The authors would also like to thank all of the Société Française de lutte contre les Cancers de l’Enfant 
et de l’Adolescent (SFCE) principal investigators: André Baruchel (Hôpital Saint-Louis/Hôpital 
Robert Debré, Paris), Claire Berger (Centre Hospitalier Universitaire, Saint-Etienne), Christophe 
Bergeron (Centre Léon Bérard, Lyon), Jean-Louis Bernard (Hôpital La Timone, Marseille), Yves 
Bertrand (Hôpital Debrousse, Lyon), Pierre Bordigoni (Centre Hospitalier Universitaire, Nancy), 
Patrick Boutard (Centre Hospitalier Régional Universitaire, Caen), Gérard Couillault (Hôpital 
d’Enfants, Dijon), Christophe Piguet (Centre Hospitalier Régional Universitaire, Limoges), Anne-
Sophie Defachelles (Centre Oscar Lambret, Lille), François Demeocq (Hôpital Hôtel-Dieu, Clermont-
Ferrand), Alain Fischer (Hôpital des Enfants Malades, Paris), Virginie Gandemer (Centre Hospitalier 
Universitaire – Hôpital Sud, Rennes), Dominique Valteau-Couanet (Institut Gustave Roussy, 
Villejuif), Jean-Pierre Lamagnere (Centre Gatien de Clocheville, Tours), Françoise Lapierre (Centre 
Hospitalier Universitaire Jean Bernard, Poitiers), Guy Leverger (Hôpital Armand-Trousseau, Paris), 
Patrick Lutz (Hôpital de Hautepierre, Strasbourg), Geneviève Margueritte (Hôpital Arnaud de 
Villeneuve, Montpellier), Françoise Mechinaud (Hôpital Mère et Enfants, Nantes), Gérard Michel 
(Hôpital La Timone, Marseille), Frédéric Millot (Centre Hospitalier Universitaire Jean Bernard, 
Poitiers), Martine Münzer (American Memorial Hospital, Reims), Brigitte Nelken (Hôpital Jeanne de 
Flandre, Lille), Hélène Pacquement (Institut Curie, Paris), Brigitte Pautard (Centre Hospitalier 
Universitaire, Amiens), Yves Perel (Hôpital Pellegrin Tripode, Bordeaux), Alain Pierre-Kahn (Hôpital 
Enfants Malades, Paris), Emmanuel Plouvier (Centre Hospitalier Régional, Besançon), Xavier 
14 
 
Rialland (Centre Hospitalier Universitaire, Angers), Alain Robert (Hôpital des Enfants, Toulouse), 
Hervé Rubie (Hôpital des Enfants, Toulouse), Nicolas Sirvent (L’Archet, Nice), Christine Soler 
(Fondation Lenval, Nice), and Jean-Pierre Vannier (Hôpital Charles Nicolle, Rouen).  
 
Funding: This work was supported by grants from INSERM, the Fondation de France, the 
Association pour la Recherche sur le Cancer (ARC), the Agence Française de Sécurité Sanitaire des 
Produits de Santé (AFSSAPS), the Agence Française de Sécurité Sanitaire de l’Environnement et du 
Travail (AFSSET), the association Cent pour sang la vie, the Institut National du Cancer (INCa), the 
Agence Nationale de la Recherche (ANR), and the Cancéropôle Ile de France. 
The authors declare no conflict of interest. 
15 
 
Table 1: Characteristics of the sample of genotyped cases and controls of European ancestry 
  Controls  ALL cases
 
 
N % 
 
N % 
Total 442 
  
434 
 
Sex and age      
Boys      
 0 - 2 yrs 47 10.6  62 14.3 
 3 - 4 yrs 27 6.1 
 
64 14.7 
 5 - 8 yrs 56 12.7 
 
51 11.8 
 9 - 14 yrs 97 21.9 
 
56 12.9 
Girls 
    
 0 - 2 yrs 59 13.3 
 
58 13.4 
 3 - 4 yrs 34 7.7 
 
52 12 
 5 - 8 yrs 45 10.2 
 
63 14.5 
 9 - 14 yrs 77 17.4 
 
28 6.5 
Birth order 
     
 1 181 41.0 
 
223 51.4 
 2 175 39.6 
 
137 31.6 
 3+ 86 19.5 
 
74 17.1 
Breastfeeding (any duration)      
 No 191 43.2 
 
225 51.8 
 Yes 251 56.8 
 
209 48.2 
Maternal educational level 
     
 No diploma 31 7.0 
 
44 10.1 
 Lower secondary diploma 102 23.1 
 
140 32.3 
 High school diploma 74 16.7 
 
79 18.2 
 University degree 235 53.2 
 
171 39.4 
Paternal educational level 
     
 No diploma 29 6.6 
 
52 12 
 Lower secondary diploma 159 36.0 
 
186 42.9 
 High school diploma 55 12.4 
 
66 15.2 
 University degree 196 44.3 
 
126 29 
 missing 3 0.7 
 
4 0.9 
Parental professional category 
     
 Intellectual/scientific jobs, managers, 
Intermediate professions 248 56.1 149 34.3 
 Administrative and sales workers 98 22.2 
 
149 34.3 
 Service workers 40 9.0 
 
57 13.1 
 Factory and agricultural workers, 
unemployed 
56 12.7 
 79 18.2 
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Table 2: Association between a reported history of asthma or eczema and childhood ALL  
 Controls  ALL  
 N=442  N=434  
 n %  n % ORa 95%CI p 
Reported asthma history 
No 399 90.3  410 94.5 1.0 Ref.  
Yes 42 9.5  24 5.5 0.6 [0.4-1.1] ns 
missing 1 0.2        
With a latency         
No 404 91.4  412 94.9 1.0 Ref.  
Yes 36 8.1  22 5.1 0.7 [0.4-1.3] ns 
missing 2 0.5       
With treatmentb   
No 409 92.5  415 95.6 1.0 Ref.  
Yes 32 7.2  19 4.4 0.7 [0.3-1.2] ns 
missing 1 0.2       
Reported eczema history 
No 346 78.3  355 81.8 1.0 Ref.  
Yes 95 21.5  77 17.7 0.8 [0.5-1.1] ns 
missing 1 0.2  2 0.5     
With a latency         
No 363 82.1  359 82.7 1.0 Ref.  
Yes 77 17.4  72 16.6 0.9 [0.6-1.3] ns 
missing 2 0.5  3 0.7      
History of asthma and/or eczema 
None 319 72.2  339 78.1 1.0 Ref.  
Asthma without eczema 27 6.1  16 3.7 0.6 [0.3-1.3]  
Eczema without asthma 79 17.9  69 15.9 0.8 [0.5-1.1]  
Asthma and eczema 15 3.4  8 1.8 0.6 [0.2-1.4] ns 
Missing 2 0.5  2 0.5     
               
Neither asthma, nor eczema 319 72.2  339 78.1 1.0 Ref.  
Asthma or eczema 122 27.6  93 21.4 0.7 [0.5-1.0] * 
missing 1 0.2  2 0.5      
 
a Odds ratios (OR) 95% confidence intervals (95%CI) estimated using a logistic regression model 
adjusted for a sex*age variable, maternal educational level, household socioprofessional category 
and birth order.   
b treatments with antihistamines, corticoids or bronchodilators 
ns: p≥0.05, * p<0.05 
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Table 3: Associations between candidate polymorphisms in IL13, IL4, IL10 and IL4R and 
childhood ALL  
Controls ALL 
N=442 N=434 
  n %   n % ORa 95%CI 
IL13-rs20541             
GG 290 65.6   268 61.8 1.0 Ref. 
AG 134 30.3   153 35.3 1.1 [0.8-1.5] 
AA 18 4.1   13 3.0 0.7 [0.3-1.6] 
AG+AA vs GG 152 34.4   166 38.2 1.0 [0.8-1.4] 
IL4 - rs2070874             
CC 334 75.6   296 68.2 1.0 Ref. 
CT 103 23.3   120 27.6 1.3 [0.9-1.8] 
TT 5 1.1   6 1.4 1.4 [0.4-5.2] 
missing       12 2.8     
CT+TT vs CC 108 24.4   126 29.0 1.3 [0.9-1.8] 
IL4-rs2243250           
CC 324 73.3   292 67.3 1.0 Ref. 
CT 112 25.3   119 27.4 1.1 [0.8-1.6] 
TT 6 1.4   6 1.4 1.0 [0.3-3.7] 
missing       17 3.9     
CT+TT vs CC 118 26.7   125 28.8 1.1 [0.8-1.5] 
IL4 haplotype           
≥1 TT 108 24.4   125 28.8 1.3 [0.9-1.8] 
IL10-rs1800896            
CC 98 22.2   88 20.3 1.0 Ref. 
CT 211 47.7   215 49.5 1.1 [0.8-1.7] 
TT 133 30.1   131 30.2 1.0 [0.7-1.5] 
CT+TT vs CC 344 77.8   346 79.7 1.1 [0.8-1.5] 
IL10-rs1800871              
GG 261 59.0   229 52.8 1.0 Ref. 
AG 153 34.6   153 35.3 1.1 [0.8-1.5] 
AA 28 6.3   20 4.6 0.9 [0.5-1.7] 
missing       32 7.4 
AG+AA vs GG 181 41.0   173 39.9 1.1 [0.8-1.5] 
IL10-rs1800872              
GG 261 59.0   229 52.8 1.0 Ref. 
GT 153 34.6   170 39.2 1.2 [0.9-1.7] 
TT 28 6.3   24 5.5 1.1 [0.6-2.1] 
missing       11 2.5     
GT+TT vs GG 181 41.0   194 44.7 1.2 [0.9-1.6] 
IL10 haplotypes              
≥1 TAT 181 41.0   173 39.9 1.1 [0.8-1.5] 
≥1 TGG 226 51.1   198 45.6 0.9 [0.6-1.1] 
IL4R-rs1801275              
AA 274 62.0   281 64.7 1.0 Ref. 
AG 154 34.8   135 31.1 0.8 [0.6-1.2] 
GG 14 3.2   18 4.1 1.3 [0.6-2.9] 
AG+GG vs AA 168 38.0   153 35.3 0.9 [0.7-1.2] 
 
a Odds ratios (OR) 95% confidence intervals (95%CI) estimated using a logistic regression model 
were adjusted for a sex*age variable, maternal educational level, household socioprofessional 
category and birth order.    
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Table 4: Gene*gene interaction analyses for the candidate polymorphisms in IL13, IL4, IL10 and 
IL4R, in childhood ALL 
   Case-control models 
Without 
interaction 
 With interaction 
   OR 95%CI  OR 95%CI p int   
IL13-rs20541 x IL4 TT haplotype    
    
  Variant IL13 rs20541 1.0 [0.7-1.4]  0.8 [0.6-1.2] 
  
  IL4 TT haplotype carrier 1.3 [0.9-1.8]  1.0 [0.6-1.6] 
  
  Variant IL13-rs20541 x IL4 haplotype    1.8 [0.9-3.5] 0.10 
 
IL13-rs20541 x IL10 TAT haplotype    
    
  Variant IL13 rs20541 1.1 [0.8-1.4]  1.3 [0.9-2.0] 
  
  IL10 TAT haplotype carrier 1.1 [0.8-1.5]  1.3 [0.9-1.9] 
  
  Variant IL13-rs20541 x IL10 haplotype    0.6 [0.3-1.1] 0.10 
 
IL13-rs20541 x IL4R-rs1801275    
    
  Variant IL13 rs20541 1.0 [0.8-1.4]  0.9 [0.6-1.4] 
  
  Variant IL4R rs1801275 0.9 [0.7-1.2]  0.8 [0.5-1.2] 
  
  Variant IL13 x variant IL4R    1.3 [0.7-2.5] ns 
 
IL4 TT haplotype x IL10 TAT haplotype      
  
  IL4 TT haplotype carrier 1.3 [1.0-1.9]  1.5 [1.0-2.3] 
  
  IL10 TAT haplotype carrier 1.1 [0.8-1.5]  1.2 [0.8-1.6] 
  
  IL4 haplotype x IL10 haplotype    0.8 [0.4-1.5] ns 
 
IL4 TT haplotype x IL4R-rs1801275    
    
  IL4 TT haplotype carrier 1.3 [0.9-1.8]  1.0 [0.7-1.5] 
  
  Variant IL4R rs1801275 0.9 [0.7-1.2]  0.8 [0.5-1.1] 
  
  IL4 haplotype x variant IL4R    1.8 [0.9-3.6] 0.07 
 
IL10 TAT haplotype x IL4R-rs1801275    
    
  IL10 TAT haplotype carrier 1.1 [0.8-1.5]  1.2 [0.8-1.7] 
  
  Variant IL4R rs1801275 0.9 [0.6-1.2]  0.9 [0.6-1.4] 
  
  IL10 haplotype x variant IL4R    0.8 [0.4-1.5] ns 
  
Odds ratios (OR) and 95% confidence intervals (95%CI) estimated using a logistic regression model 
adjusted for a sex*age variable, maternal educational level, household socioprofessional category 
and birth order.  
p int: p for interaction test;  ns: p>0.10 
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Table 5: Interaction analyses between the candidate polymorphisms and a reported history of 
asthma or eczema, in childhood ALL 
Asthma Eczema Asthma or eczema 
OR 95%CI  p int OR 95%CI  p int OR 95%CI  p int 
IL13-rs20541 
Medical history vs no 0.5 [0.3-1.1] 0.6 [0.4-1.0] 0.6 [0.4-0.9] 
≥1 variant allele vs none 1.0 [0.7-1.4] 0.9 [0.7-1.3] 0.9 [0.6-1.2] 
Interaction history x allele 1.8 [0.5-6.0] ns 1.7 [0.8-3.7] ns 1.9 [0.9-3.8] 0.07 
IL4-rs2070874 
Medical history vs no 0.6 [0.3-1.3] 0.7 [0.5-1.1] 0.7 [0.4-1.0] 
≥1 variant allele vs none 1.3 [0.9-1.9] 1.3 [0.9-1.9] 1.3 [0.9-1.9] 
Interaction history x allele 0.9 [0.3-2.9] ns 0.9 [0.4-2.0] ns 1.1 [0.5-2.2] ns 
IL4-rs2243250 
Medical history vs no 0.7 [0.3-1.3] 0.7 [0.5-1.2] 0.7 [0.4-1.0] 
≥1 variant allele vs none 1.2 [0.8-1.6] 1.1 [0.8-1.7] 1.1 [0.8-1.6] 
Interaction history x allele 0.8 [0.2-2.8] ns 0.9 [0.4-2.0] ns 1.1 [0.5-2.3] ns 
IL4 TT haplotype 
Medical history vs no 0.6 [0.3-1.3] 0.7 [0.5-1.2] 0.7 [0.4-1.0] 
≥1 variant allele vs none 1.3 [0.9-1.9] 1.3 [0.9-1.9] 1.3 [0.9-1.9] 
Interaction history x allele 0.9 [0.3-2.9] ns 0.9 [0.4-2.0] ns 1.0 [0.5-2.2] ns 
IL10-rs1800896 
Medical history vs no 0.9 [0.3-2.6] 0.9 [0.4-2.2] 0.8 [0.4-1.7] 
≥1 variant allele vs none 1.1 [0.8-1.6] 1.2 [0.8-1.7] 1.2 [0.8-1.7] 
Interaction history x allele 0.7 [0.2-2.4] ns 0.8 [0.3-1.9] ns 0.8 [0.4-2.0] ns 
IL10-rs1800871 
Medical history vs no 1.1 [0.5-2.3] 0.9 [0.6-1.5] 1.0 [0.6-1.5] 
≥1 variant allele vs none 1.2 [0.9-1.6] 1.2 [0.9-1.7] 1.3 [0.9-1.8] 
Interaction history x allele 0.3 [0.1-1.0] 0.04 0.6 [0.3-1.2] ns 0.5 [0.2-1.0] 0.04 
IL10-rs1800872 
Medical history vs no 1.1 [0.5-2.3] 0.9 [0.6-1.5] 1.0 [0.6-1.5] 
≥1 variant allele vs none 1.4 [1.0-1.8] 1.4 [1.0-1.9] 1.5 [1.0-2.0] 
Interaction history x allele 0.2 [0.1-0.8] 0.02 0.6 [0.3-1.3] ns 0.5 [0.3-1.0] 0.06 
IL10 TAT haplotype 
Medical history vs no 1.1 [0.5-2.3] 0.9 [0.6-1.5] 1.0 [0.6-1.5] 
≥1 variant allele vs none 1.2 [0.9-1.6] 1.2 [0.9-1.7] 1.3 [0.9-1.8] 
Interaction history x allele 0.3 [0.1-1.0] 0.04 0.6 [0.3-1.2] ns 0.5 [0.2-1.0] 0.04 
IL4R-rs1801275 
Medical history vs no 0.4 [0.2-0.8] 0.8 [0.5-1.3] 0.7 [0.4-1.0] 
≥1 variant allele vs none 0.8 [0.6-1.1] 0.9 [0.7-1.3] 0.9 [0.6-1.2] 
Interaction history x allele 3.7 [1.1-12.6] 0.04 0.8 [0.4-1.8] ns 1.2 [0.6-2.4] ns 
 
Odds ratios (OR) and 95% confidence intervals (95%CI) estimated using a logistic regression model 
adjusted for a sex*age variable, maternal educational level, household socioprofessional category 
and birth order.  
p int: p for interaction test; ns: p>0.10  
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